shelf(0)

No. 006 · Repair · Neuroprotective

ARA-290

CibinetideARA 290Helix B surface peptide

A Tier A · Controlled human trials how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
ARA-290 (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER A — At least one published randomized controlled trial in humans.

Small randomized, placebo-controlled phase 2 trials have been published (sarcoidosis-associated small-fiber neuropathy, type 2 diabetes); not approved.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved Granted orphan designation for sarcoidosis; no approval.
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

An erythropoietin-derived peptide that activates the innate repair receptor without stimulating red blood cell production. Investigated for neuropathic pain and tissue protection.

Research status Phase II clinical trials for sarcoidosis-related neuropathy; published human safety and efficacy data

04

Mechanism

ARA-290 is an 11-amino-acid peptide derived from the helix B surface of erythropoietin that selectively activates the innate repair receptor (IRR), a heterodimer of the EPO receptor and beta common receptor. This triggers anti-apoptotic and anti-inflammatory signaling through JAK2/STAT5 without stimulating erythropoiesis.

05

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Neuropathic pain reduction
  • Nerve fiber regeneration
  • Anti-inflammatory tissue protection
  • Improved metabolic parameters in diabetic neuropathy
06

Safety & unknowns

Phase II human trial data show acceptable safety with no erythropoietic stimulation. Mild injection site reactions reported. Not FDA-approved. Orphan drug designation for sarcoidosis.

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [0]

No studies cited for this entry yet.

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). ARA-290. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/ara-290/

$ cite --format=bibtex 
@misc{peptidemeta-ara-290,
  title = {ARA-290},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/ara-290/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open